Is CUE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CUE. It does not provide personalized investment advice.

CUE (Cue Biopharma, Inc.) Stock Analysis - Financials

Cue Biopharma, Inc. (CUE) is a publicly traded Healthcare sector company. As of July 13, 2026, CUE trades at $30.91 with a market cap of $154.49M and a P/E ratio of -25.75. CUE moved -15.72% today. Year to date, CUE is +305.42%; over the trailing twelve months it is +54.02%. Its 52-week range spans $4.97 to $52.50. Rallies surfaces CUE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are CUE's key financials?

CUE financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CUE recently traded at $30.91. Market cap is $154.49M. P/E ratio is -25.75. Revenue is $32.73M.

CUE Key Metrics

Key financial metrics for CUE
Metric	Value
Price	$30.91
Market Cap	$154.49M
P/E Ratio	-25.75
EPS	$-1.21
Dividend Yield	0.00%
52-Week High	$52.50
52-Week Low	$4.97
Volume	184.31K
Avg Volume	0
Revenue (TTM)	$32.73M
Net Income	$-19.52M
Gross Margin	0.00%

CUE Analyst Consensus

CUE analyst coverage data. Average price target: $0.00.

Common questions about CUE

What are CUE's key financials?: CUE financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CUE recently traded at $30.91. Market cap is $154.49M. P/E ratio is -25.75. Revenue is $32.73M.
Is CUE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CUE. It does not provide personalized investment advice.